Arthritis
Array BioPharma's p38 inhibitor for inflammatory disease to advance into human trials
Published in Medical Letter on the CDC and FDA, December 3rd, 2006
ARRY-797 is a potent, selective, orally active inhibitor of p38 MAP kinase and has demonstrated good tolerability and significant efficacy in preclinical models of human inflammatory diseases. The compound will initially be evaluated in dose escalation studies in normal, healthy volunteers for safety, exposure and inhibition of mechanism-related biomarkers.
"Advancing ARRY-797, our small molecule p38 inhibitor, into clinical trials is a significant achievement...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Acromegaly
Tercica partner Ipsen submits NDA to U.S. FDA for Somatuline Autogel for treating acromegaly - Addiction Medicine
US WorldMeds initiates phase 3 trial of lofexidine for treating opiate withdrawal symptoms - Age-Related Macular Degeneration
Results of implantable telescope trial show potential for treatment of AMD - Amyotrophic Lateral Sclerosis
CytRx's Arimoclomol granted Orphan Drug Designation in European Union for treatment of ALS - Awards
CytRx CEO receives Lou Gehrig Memorial Award - Breast Cancer
Bionovo's phase I/II trial protocol for metastatic breast cancer accepted by U.S. FDA - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
